← Back to all trials
Enrolling By Invitation
NCT05059626
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee
Conditions: Endometriosis
Sex: Female
Ages: 18 Years – 45 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 28
Sponsor: Penn State University
Location: The John B. Pierce Laboratory New Haven Connecticut
Summary
Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis.
Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.
Eligibility Criteria
Inclusion Criteria:
* Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \140/90
* Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
* Pregnancy
* Breastfeeding
* Taking illicit and/or recreational drugs
* Abnormal liver function
* Rash, skin disease, disorders of pigmentation, known skin allergies
* Diagnosed or suspected metabolic or cardiovascular disease
* Persistent unexplained elevations of serum transaminases
* Known allergy to latex or investigative substances
Source: ClinicalTrials.gov (NCT05059626). StuddyBuddy aggregates publicly available trial information.